Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Drug improves sexual function for patients with depression, study finds (opens in a new tab)

medicalxpress.com · 2026-09-15

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Three of five claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 3 supported
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredThe researchers also found that participants who received add-on lumateperone saw significant improvements in depressive symptoms and sexual function by the end of the 43-day treatment period, and that women appeared to benefit more than men, although the researchers said more research is needed to verify that.View evidenceHide evidence

As stated43-day treatment period

Why this verdict

The sexual-function improvement by Day 43 is supported, and the women-versus-men pattern is broadly supported with appropriate hedging: women showed a significant effect while men did not reach conventional significance. But the claim that participants had significant improvements in depressive symptoms is not verifiable from the abstract-level profile, which only notes a hedged possible link between depressive-symptom improvement and sexual-function improvement and provides no depression-outcome effect estimate or statistical test.

1

Study evidence

In the ITT population (N=480), adjunctive lumateperone 42 mg + ADT produced a statistically significant improvement in CSFQ-14 total score at Day 43 versus placebo + ADT.LSMD = 2.7; ES = 0.38; P < .0001

“Randomized phase 3 Study 502 (NCT05061706) investigated the impact of adjunctive lumateperone 42 mg/day on sexual functioning, per Changes in Sexual Functioning Questionnaire 14-item version (CSFQ-14).”
2

Study evidence

Overall ITT: adjunctive lumateperone 42 mg+ADT improved CSFQ-14 Total score at Day 43 versus placebo+ADT.LSMD=2.7; ES=0.38; P<.0001

“Results: Of 480 patients in the ITT population, 82.5% had sexual dysfunction at baseline (women=284; men=112).”
Claim 2 of 5Not coveredAt the beginning of the trial, 82.5% of participants had sexual dysfunction; by the end, more than a quarter reported regular sexual function, and participants without sexual dysfunction did not report worsening during the trial.View evidenceHide evidence

As stated82.5%; more than a quarter

Why this verdict

The profile supports that 82.5% of the ITT population had sexual dysfunction at baseline and that participants without baseline sexual dysfunction showed no change/no worsening. The statement that by the end more than a quarter reported regular sexual function is not present in the supplied abstract-level profile, so that part is not verifiable at this depth.

1

Study evidence

In the ITT population (N=480), adjunctive lumateperone 42 mg + ADT produced a statistically significant improvement in CSFQ-14 total score at Day 43 versus placebo + ADT.LSMD = 2.7; ES = 0.38; P < .0001

“Randomized phase 3 Study 502 (NCT05061706) investigated the impact of adjunctive lumateperone 42 mg/day on sexual functioning, per Changes in Sexual Functioning Questionnaire 14-item version (CSFQ-14).”
2

Study evidence

Overall ITT: adjunctive lumateperone 42 mg+ADT improved CSFQ-14 Total score at Day 43 versus placebo+ADT.LSMD=2.7; ES=0.38; P<.0001

“Results: Of 480 patients in the ITT population, 82.5% had sexual dysfunction at baseline (women=284; men=112).”
Claim 3 of 5SupportedPatients with major depressive disorder and an inadequate response to standard antidepressants who received add-on treatment with lumateperone had significantly improved sexual function, according to a new study led by a University of Virginia School of Medicine researcher.View evidenceHide evidence

As statedsignificantly improved

Why this verdict

The abstract-level profile supports the main scientific claim: in an RCT of adults with MDD and inadequate response to antidepressants, adjunctive lumateperone 42 mg/day significantly improved CSFQ-14 total sexual-function score at Day 43 versus placebo. The profile does not verify the University of Virginia leadership detail, but the sexual-function claim itself is supported.

1

Study evidence

In the ITT population (N=480), adjunctive lumateperone 42 mg + ADT produced a statistically significant improvement in CSFQ-14 total score at Day 43 versus placebo + ADT.LSMD = 2.7; ES = 0.38; P < .0001

“Randomized phase 3 Study 502 (NCT05061706) investigated the impact of adjunctive lumateperone 42 mg/day on sexual functioning, per Changes in Sexual Functioning Questionnaire 14-item version (CSFQ-14).”
Claim 4 of 5SupportedIn a study of 480 patients, patients randomized to receive a daily 42 mg dose of lumateperone added to their antidepressant therapy had significant improvements in sexual function compared with patients whose additional treatment was a placebo.View evidenceHide evidence

As stated480 patients; daily 42 mg dose

Why this verdict

Supported. The profile reports an ITT population of N=480 randomized to 6 weeks of lumateperone 42 mg/day plus antidepressant therapy versus placebo plus antidepressant therapy, with statistically significant CSFQ-14 total improvement at Day 43 favoring lumateperone.

1

Study evidence

In the ITT population (N=480), adjunctive lumateperone 42 mg + ADT produced a statistically significant improvement in CSFQ-14 total score at Day 43 versus placebo + ADT.LSMD = 2.7; ES = 0.38; P < .0001

“Randomized phase 3 Study 502 (NCT05061706) investigated the impact of adjunctive lumateperone 42 mg/day on sexual functioning, per Changes in Sexual Functioning Questionnaire 14-item version (CSFQ-14).”
Claim 5 of 5SupportedImprovements were seen across multiple patient groups, including those with baseline sexual dysfunction, women, younger and older adults, and across desire, arousal, orgasm and pleasure.View evidenceHide evidence

Why this verdict

Supported at abstract depth. The profile reports improvements among patients with baseline sexual dysfunction, in women, across age groups, and across CSFQ domain scores. However, the abstract-level profile does not provide full domain-level estimates or multiplicity details.

1

Study evidence

Overall ITT: adjunctive lumateperone 42 mg+ADT improved CSFQ-14 Total score at Day 43 versus placebo+ADT.LSMD=2.7; ES=0.38; P<.0001

“Results: Of 480 patients in the ITT population, 82.5% had sexual dysfunction at baseline (women=284; men=112).”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Domain and age-group analyses found significant improvements across age groups and CSFQ domains, but the abstract does not provide all domain-level estimates, confidence intervals, or multiplicity-adjustment details.

    The story reports the favorable domain and age-group findings, but it does not mention the abstract-level limitation that detailed numeric estimates and adjustment/prespecification information are unavailable.

    From Within-RCT subgroup and domain analyses

  • The paper’s depressive-symptom element is framed as a hedged interpretive statement that improvements in depressive symptoms may be linked to improvements in sexual functioning; the abstract profile does not describe a separate mediation/correlation analysis or provide depression-effect statistics.

    The story frames depressive-symptom improvement as a significant finding alongside sexual-function improvement, which is stronger than the supplied abstract-level profile supports.

    From Narrative interpretation/clinical inference

  • The trial duration was short: 6 weeks/Day 43, limiting inference about longer-term sexual-function benefits or harms.

    The story states the 43-day treatment period but does not present short duration as a limitation on long-term conclusions.

    From Randomized, placebo-controlled adjunctive pharmacotherapy trial (phase 3); Within-RCT subgroup and domain analyses

4 things the story did carry across
  • The paper’s core design was a randomized, placebo-controlled phase 3 trial of adjunctive lumateperone 42 mg/day plus ongoing antidepressant therapy versus placebo plus antidepressant therapy in adults with MDD and inadequate response to 1–2 antidepressants; ITT N=480; treatment lasted 6 weeks with Day 43 assessment.
  • The primary sexual-function result was a statistically significant improvement in CSFQ-14 total score at Day 43 favoring lumateperone versus placebo.
  • Subgroup findings showed greater improvement among participants with baseline sexual dysfunction and no change/no worsening among those without baseline sexual dysfunction.
  • Sex-specific results were heterogeneous: women showed a statistically significant CSFQ-14 total improvement, while men showed a smaller non-significant result; the abstract profile does not report an interaction test.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoDetermine whether adjunctive lumateperone 42 mg/day added to ongoing antidepressant therapy improves (or at least does not worsen) sexual functioning in adults with major depressive disorder and inadequate response to 1–2 antidepressants, as measured by CSFQ-14 over 6 weeks versus placebo adjunct.Randomized, placebo-controlled adjunctive pharmacotherapy trial (phase 3)Expand

In plain English

Randomized, double-arm phase 3 trial (Study 502, NCT05061706) testing adjunctive lumateperone 42 mg/day versus placebo added to ongoing antidepressant therapy for 6 weeks in adults with major depressive disorder and inadequate response to 1–2 antidepressants. Sexual function was measured by the Changes in Sexual Functioning Questionnaire (CSFQ-14) in the ITT population (N=480). Adjunctive lumateperone produced a statistically significant improvement in CSFQ-14 total score at Day 43 versus placebo; subgroup and domain analyses reported larger effects in those with baseline sexual dysfunction and in women, while men did not show a statistically significant change. The abstract notes that improvements in depressive symptoms may be linked to improvements in sexual functioning. The authors conclude adjunctive lumateperone did not worsen sexual functioning or cause treatment-related sexual dysfunction over 6 weeks.

Key findings

  • In the ITT population (N=480), adjunctive lumateperone 42 mg + ADT produced a statistically significant improvement in CSFQ-14 total score at Day 43 versus placebo + ADT.LSMD = 2.7; ES = 0.38; P < .0001
  • Patients with baseline sexual dysfunction showed greater improvement on CSFQ-14 total with lumateperone than placebo.LSMD = 3.1; ES = 0.42; P < .0001
“Randomized phase 3 Study 502 (NCT05061706) investigated the impact of adjunctive lumateperone 42 mg/day on sexual functioning, per Changes in Sexual Functioning Questionnaire 14-item version (CSFQ-14).”
What this piece can’t prove
  • Duration limited to 6 weeks; abstract does not provide longer-term follow-up for sexual functioning.

3 further details could not be confirmed from the summary.

2human in vivoCharacterize heterogeneity of sexual-function effects (CSFQ-14 total and domains) across clinically relevant subgroups (eg, baseline sexual dysfunction status, sex, age) within the trial population.Within-RCT subgroup and domain analysesExpand

In plain English

Within the randomized, double‑arm phase 3 Study 502 (NCT05061706) of adjunctive lumateperone 42 mg/day versus placebo added to ongoing antidepressant therapy in adults with MDD and inadequate response to 1–2 ADTs, subgroup and CSFQ-14 domain analyses at Day 43 showed overall improvement in sexual functioning with lumateperone, with heterogeneous effects across baseline sexual-dysfunction status, sex, and domains. Improvements were concentrated among participants with baseline sexual dysfunction and were statistically significant in women but not in men; pleasure and arousal/excitement domains improved across sexes and age groups. Findings are drawn from the trial ITT population (n=480) as reported in the abstract.

Key findings

  • Overall ITT: adjunctive lumateperone 42 mg+ADT improved CSFQ-14 Total score at Day 43 versus placebo+ADT.LSMD=2.7; ES=0.38; P<.0001
  • Patients with baseline sexual dysfunction experienced greater improvement in CSFQ-14 Total score with lumateperone versus placebo, while those without baseline dysfunction showed no change.LSMD=3.1; ES=0.42; P<.0001
“Results: Of 480 patients in the ITT population, 82.5% had sexual dysfunction at baseline (women=284; men=112).”
What this piece can’t prove
  • Short treatment duration (6 weeks/Day 43) limits inference about longer-term sexual-function effects.
  • Subgroup analyses may be underpowered (notably the male subgroup) and the abstract does not report interaction tests or adjustment for multiple comparisons.

2 further details could not be confirmed from the summary.

3otherExplore/argue that improvement in depressive symptoms may be linked to observed improvement in sexual functioning during adjunctive lumateperone treatment.Narrative interpretation/clinical inferenceExpand

In plain English

The abstract includes an interpretive statement that "Improvements in depressive symptoms may be linked to improvement in sexual functioning" in the 6-week randomized adjunctive lumateperone trial. This is presented as a hedged, narrative inference rather than as a separately described statistical analysis in the abstract; no mediation, correlation, or other quantitative linkage methods are reported there.

Key findings

  • The authors state that improvements in depressive symptoms may be linked to improvement in sexual functioning during adjunctive lumateperone treatment.
“Improvements in depressive symptoms may be linked to improvement in sexual functioning.”
What this piece can’t prove
  • Abstract does not report a distinct analytic method (eg, mediation or correlation) to support the linkage claim.
  • Statement is interpretive and hedged, limiting certainty about the relationship.
  • Causal inference cannot be drawn from the provided text; the assertion may reflect concurrent improvements rather than a tested causal pathway.
  • Summary is based solely on the abstract; absence of details may be due to omission rather than absence of analysis in full paper.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 34 candidate papers

And 28 more candidates considered.